Nano Cap New Millennium Growth Fund L P Invests $838,000 in SiBone $SIBN

Nano Cap New Millennium Growth Fund L P bought a new position in SiBone (NASDAQ:SIBN) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 42,500 shares of the company’s stock, valued at approximately $838,000. Nano Cap New Millennium Growth Fund L P owned about 0.10% of SiBone as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of SIBN. ANTIPODES PARTNERS Ltd bought a new stake in shares of SiBone in the 4th quarter worth approximately $29,000. State of Alaska Department of Revenue bought a new stake in shares of SiBone in the 3rd quarter worth approximately $39,000. State of Wyoming bought a new stake in shares of SiBone in the 2nd quarter worth approximately $55,000. Canada Pension Plan Investment Board bought a new stake in shares of SiBone in the 2nd quarter worth approximately $68,000. Finally, Larson Financial Group LLC raised its holdings in shares of SiBone by 42.3% in the 4th quarter. Larson Financial Group LLC now owns 3,569 shares of the company’s stock worth $70,000 after purchasing an additional 1,061 shares during the period. Institutional investors own 98.11% of the company’s stock.

SiBone Trading Down 0.1%

Shares of SIBN stock opened at $14.81 on Friday. The company’s fifty day simple moving average is $13.38 and its two-hundred day simple moving average is $16.10. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.99 and a quick ratio of 8.34. SiBone has a 1 year low of $11.48 and a 1 year high of $21.89. The stock has a market capitalization of $656.82 million, a price-to-earnings ratio of -37.97 and a beta of 0.67.

SiBone (NASDAQ:SIBN) last issued its earnings results on Monday, May 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.07. SiBone had a negative net margin of 8.10% and a negative return on equity of 9.56%. The business had revenue of $52.59 million for the quarter, compared to analysts’ expectations of $51.16 million. As a group, analysts anticipate that SiBone will post -0.44 earnings per share for the current year.

Insider Buying and Selling at SiBone

In other SiBone news, CEO Laura Francis sold 14,957 shares of the business’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $14.71, for a total transaction of $220,017.47. Following the sale, the chief executive officer owned 503,444 shares of the company’s stock, valued at $7,405,661.24. The trade was a 2.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Anshul Maheshwari sold 3,318 shares of the business’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $12.87, for a total transaction of $42,702.66. Following the sale, the chief financial officer directly owned 263,148 shares in the company, valued at $3,386,714.76. The trade was a 1.25% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 29,572 shares of company stock worth $418,831. 4.00% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. TD Cowen lowered their price target on shares of SiBone from $22.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, May 12th. Wall Street Zen cut shares of SiBone from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $18.00 price target (down from $20.00) on shares of SiBone in a report on Tuesday, May 12th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $23.00.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.